新型冠状病毒广谱免疫优势CD4+T细胞表位肽及其应用
By constructing a Th epitope prediction tool and synthesizing Th epitope peptide-MHC tetramer, the problem of identifying novel coronavirus epitope peptides was solved, achieving efficient detection of CD4+ T cell activation and immune response, which is suitable for the broad-spectrum design of COVID-19 vaccines.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ARMY MEDICAL UNIV
- Filing Date
- 2024-07-17
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies are insufficient to effectively identify novel coronavirus epitope peptides presented by MHC-II molecules, affecting the immunization efficacy and response of COVID-19 vaccines, and there is a lack of broad-spectrum vaccine designs targeting individuals with different HLA supertypes.
A Th epitope prediction tool was constructed using a site scoring matrix algorithm to predict Th epitope peptides of the novel coronavirus and its variants. Th epitope peptide-MHC tetramers were synthesized for use in detecting the immune response of CD4+ T cells and preparing peptide vaccines.
It improves the predictive accuracy and practicality of Th epitope peptides, reduces economic costs, can stimulate CD4+ T cell activation, detect immune status after vaccination and viral infection, and is applicable to the development of COVID-19 vaccines for individuals with different HLA supertypes.
Smart Images
Figure CN119320428B_ABST